Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TraPIN: Pazopanib + Trabectedin + Ipilimumab + Nivolumab in Recurrent Soft Tissue Sarcomas
NCT07444619Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2026
- Primary completion
- Dec 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pazopanib in soft tissue sarcoma (STS), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Safety and Adverse Events at 1 year and Maximum Tolerated Dose / Recommended Phase 2 Dose at 1 year. Started Jun 2026; status: recruiting.
02
Drugs
pazopanib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT07444619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07444619.